A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 618 participants.

Also called NCT07295418

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 618 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07295418
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07295418. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-23 (actual); primary completion 2025-04-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia
Condition
Hyperlipidemias
Intervention (Drug)
SAL003 140 mg
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)
Collaborator
Salubris (Chengdu) Biotechnology Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct07295418
Content hash
d7da155225fff9a2e43bae6d1e9e15a367a9239ef9da0e111a27f1ac7144046c